MG
Montreal Gazette
›The AI Power Surge: Why Energy Infrastructure Is Becoming the Next Critical Bottleneck›Cycurion, Inc. Provides Update on Revised Memorandum of Understanding to Acquire Kustom Entertainment’s Legacy Video Solutions Segment›Oncotelic Therapeutics Inc. (OTCQB: OTLC) Leveraging Expertise amid Evaluation Evolution›SPARC AI Inc. (OTC: SPAIF) Offers Software-Based Solution Designed for New Operational Reality›POSaBIT Launches New AI-Driven Producer & Processor Portal: POSaBIT Brands›Enveric Biosciences to Participate in a Panel Discussion at Needham’s Virtual Psychedelics Forum›CellCarta Eliminates 9-Hours-Per-Week Regulatory Bottleneck with RegASK’s AI-Driven Intelligence Platform›Thermal Concepts Announces the Acquisition of Hunter Mechanical LLC, Expanding into the Mid-Atlantic Market›GTT Announces 2026 Strategy: Expanding Cloud and Security Capabilities to Dynamically Protect Global Enterprise Infrastructures›Moody’s Advances Decision-Grade Credit Intelligence Across Enterprise AI Workflows, Powered by Microsoft 365 Copilot›AV Successfully Demonstrates LOCUST Laser Weapon System Aboard USS George H.W. Bush›Responding to Customer Demand, Starlink High-Speed Connectivity Now Available as an Aftermarket Option on the Cessna Citation Ascend; 560XL Series Achieves EASA Certification›VERSES® Expands Commercial Relationship with Major Global Investment Firm›DIRTT Reports March Commercial Activity Reflecting Demand for Faster, More Cost-Certain Construction Solutions›Textron Aviation Announces Fleet Order From LUMINAIR to Operate Nine Best-selling Cessna Citation Latitude Midsize Business Jets, Supporting Charter Operations Across Europe›ZenaTech Continues International Expansion Opening New Offices in South Korea and the United Kingdom›BULGOLD Announces Closing of Non-Brokered Private Placement for Gross Proceeds of Approximately $1.17 Million›DEEP SEA MINERALS CORP. COMMENTS ON AMERICAN OCEAN MINERALS – ODYSSEY MARINE EXPLORATION TRANSACTION›Medicenna Presents Positive Data Demonstrating Superior Safety and Efficacy Potential of its First-in-Class anti-PD-1 x IL-2 Bifunctional Superkine MDNA113 at AACR 2026›Annual General and Special Meeting of Shareholders to be held May 7, 2026
Last updated: May 3, 2026, 2:00 a.m.